HealthLumen

Virtual populations. Real decisions.

Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.

[HealthLumen @HealthLumen]

NCDs are the #1 cause of death and disability worldwide - yet much of this burden is preventable.

At the 10th @POLITICO Health Care Summit, prevention took centre stage: with discussions on earlier diagnosis, better health literacy and more.

Read here:
https://t.co/HXbdw8NWTh

[HealthLumen @HealthLumen]

Millions with #CKD may have rare kidney diseases that remain hidden or misdiagnosed.

Our new article with @pharmaphorum shows how data-driven insights can support the case for earlier diagnosis, more efficient policy & better care for CKD patients.

👉 https://t.co/SJj4wavglb

[HealthLumen @HealthLumen]

Building a strong Target Product Profile (TPP) starts with understanding patient biology.

💡 Genetic stratification helps drug developers:
✔️ Define target populations
✔️ Design smarter trials
✔️ Strengthen value propositions

Read more here👉 https://t.co/81OEzXSJi8

[HealthLumen @HealthLumen]

📣 Just 2 days to go!

Accurately estimating rare disease prevalence is a key challenge in rare disease research and drug development – join our live AlleleAtlas demo session this Thursday to learn how this free tool can support you.

🔗 Register here: https://t.co/pKNgS5a5hP

[HealthLumen @HealthLumen]

Accurately estimating rare disease prevalence is challenging – but essential for efficient drug development.

Join our live AlleleAtlas demo on 24 July to see how this free tool can help you better understand your rare disease of interest.

🔗 Register: https://t.co/pKNgS5a5hP

[HealthLumen @HealthLumen]

💰 In 2023, preventable cases of 5 key diseases in Canadian men cost $12.4B.

🏥 Our research for @Movember supports urgent calls for policies that prioritise prevention and better disease management.

🔗 Read a full summary of our research here: https://t.co/kVUxMZHpJO

[HealthLumen @HealthLumen]

We are pleased to be sponsoring the “Priorities for rare disease diagnosis, care and treatment in England” online conference, hosted by @wfpevents on June 5th, 2025.

Register now to help advance rare disease diagnosis, therapy access & data innovation.

🔗https://t.co/aVrP3LqdQ5

[HealthLumen @HealthLumen]

How can we reduce uncertainty in #RareDisease prevalence estimates?

🧬 In our newest blog, we put the spotlight on #LysosomalStorageDisorders & show how #GeneticDatabase analysis can help improve understanding of rare disease populations.

🔗https://t.co/zSq8zUAhJX

[HealthLumen @HealthLumen]

🌍 The theme for #WorldKidneyDay 2025 is: "Detect early, protect kidney health".

1 in 10 are affected with CKD worldwide, and many go undiagnosed until costly and invasive treatments are required.

🔗 Read more about the importance of early detection here https://t.co/uZGTcI23WM

[HealthLumen @HealthLumen]

#RareDiseaseDay is a time to reflect on the progress made in the past year – and the challenges that remain.

Some 2024 key advances:
🏛️ @FDA policy updates
💊 Orphan drugs made up 52% of FDA approvals
🧬 Breakthroughs in AI-driven diagnostics

Read more> https://t.co/UVZNw32iNe

[HealthLumen @HealthLumen]

🧬 #Fabrydisease may be 3 times more prevalent than current estimates suggest, according to HealthLumen’s recent genetic database analysis study.

📖 Find out more in our most recent blog post>> https://t.co/BIyoY8X8Vv

#raredisease

[HealthLumen @HealthLumen]

🧪 Can GLP-1 receptor agonist treatments help reduce #obesity-related disease?

📉 HealthLumen's #microsimulation study commissioned by @nesta_uk found that these treatments could significantly help lower rates of #T2D, #CVD, and #cancer.

📖 Read more>> https://t.co/VGMo7I6EDO

[HealthLumen @HealthLumen]

🩺New research suggests England could face £1.2B in healthcare costs if Covid-19 alcohol consumption trends persist to 2035, with disadvantaged groups hit hardest.

Explore our latest blog for key findings>> https://t.co/YnEX35Quz2

#alcohol #covid19 #NCDs

[HealthLumen @HealthLumen]

🧬 Cascade screening provides a targeted approach to genetic testing that can transform the lives of #raredisease patients by enabling timely interventions that improve outcomes.

📖 Explore how these benefits can be quantified in our recent blog post>> https://t.co/USKarnmqWt

[HealthLumen @HealthLumen]

The Inside CKD online portal is live!

Part of @AstraZeneca's ACT on CKD programme, Inside CKD projects the clinical & economic burden of CKD (2022-2027) across 31 countries. The online portal provides a key tool for policymakers driving change.

https://t.co/EKBuss2Uns

#CKD

[HealthLumen @HealthLumen]

Today, HealthLumen launches AlleleAtlas, a tool that uses data from the #gnomAD genetic database to estimate the prevalence of #raregeneticdiseases.

The tool aims to help all those engaged in advancing #raredisease research and therapeutics.

AlleleAtlas> https://t.co/3pfaV9XS1J

[HealthLumen @HealthLumen]

On #WorldDiabetesDay, we’re reminded that diabetes impacts 530M+ people globally – and the numbers are rising.

HealthLumen's new research points to several cost-saving policies that could work to reduce type 2 diabetes incidence over a 5-year period.

https://t.co/PiVl8T0eUU

[Rallybio @rallybio]

🧑‍🔬‍ Amanda Hayward, Head of Global Business Development presented our research, in partnership with @HealthLumen, on quantifying the proportion of women at risk of an FNAIT pregnancy in diverse populations in the United States at NORD 2024 today.

[HealthLumen @HealthLumen]

HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences this year.

We look forward to seeing you there.

https://t.co/EqjWbHmvUI

[HealthLumen @HealthLumen]

The results of our genetic database analysis study conducted in partnership with @Rallybio on FNAIT risk across ethnically diverse populations will be presented at the @GeneticsSociety 2024 Annual Meeting on November 5–9 2024.

https://t.co/iTufM1GuXQ

#FNAIT #RareDisease